Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2828216 | 0.86 | NR1H2 (0.39) | USP2SMN1; SMN2NR1H2ALDH1A1MEN1 | |
| SCHEMBL2825203 | 0.86 | USP2 (0.37) | USP2SMN1; SMN2NR1H2ALDH1A1MEN1 | |
| SCHEMBL3024254 | 0.84 | USP2 (0.43) | USP2ALDH1A1MEN1KMT2A | |
| SCHEMBL15459809 | 0.84 | USP2 (0.40) | USP2SMN1; SMN2NR1H2ALDH1A1MEN1 | |
| SCHEMBL2726581 | 0.84 | USP2 (0.41) | USP2SMN1; SMN2NR1H2ALDH1A1MEN1 | |
| SCHEMBL30856581 | 0.84 | USP2 (0.41) | USP2SMN1; SMN2NR1H2ALDH1A1MEN1 | |
| SCHEMBL15251321 | 0.83 | NR1H2 (0.36) | USP2SMN1; SMN2NR1H2ALDH1A1MEN1 | |
| SCHEMBL2821808 | 0.83 | NR1H2 (0.36) | USP2SMN1; SMN2NR1H2ALDH1A1MEN1 | |
| SCHEMBL2822607 | 0.83 | NR1H2 (0.36) | USP2SMN1; SMN2NR1H2ALDH1A1MEN1 | |
| SCHEMBL2826407 | 0.82 | NR1H2 (0.36) | USP2SMN1; SMN2NR1H2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023150186-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| EP-2651417-B1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | CALCHAN LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| EP-2651417-B1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | CALCHAN LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-20100203039-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| US-20100203039-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| US-7700624-B2 | 3-aminocyclopentanecrboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700624-B2 | 3-aminocyclopentanecrboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700624-B2 | 3-aminocyclopentanecrboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1971576-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070149532-A1 | 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149532-A1 | 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| WO-2007072201-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149532-A1 | 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | USP2 2154/4885SMN1; SMN2 2660/4885NR1H2 2671/4885 |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | USP2 2154/4885SMN1; SMN2 2660/4885NR1H2 2671/4885 |
| US-20100203039-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | USP2 3974/4885SMN1; SMN2 4760/4885NR1H2 159/4885 |
| US-20070149532-A1 | 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors | CCR5, CCR2, ACKR3 | USP2 4055/4885SMN1; SMN2 4747/4885NR1H2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.